Overview

A Study of Abemaciclib (LY2835219) in Combination With Temozolomide and Irinotecan and Abemaciclib in Combination With Temozolomide in Children and Young Adult Participants With Solid Tumors

Status:
Recruiting

Trial end date:
2023-12-21

Target enrollment:

Participant gender:

Summary

The study's purpose is to see if the drug abemaciclib is safe and effective in combination with temozolomide and irinotecan (Part A) and abemaciclib in combination with temozolomide (Part B) in pediatric and young adult participants with relapsed/refractory solid tumors.

Phase:

Phase 1

Details

Lead Sponsor:

Eli Lilly and Company

Treatments:

Irinotecan
Temozolomide